Please login to the form below

Not currently logged in
Email:
Password:

Omthera Pharmaceuticals

This page shows the latest Omthera Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

FDA approves AZ’s fish oil drug

FDA approves AZ’s fish oil drug

It was originally developed by Omthera Pharmaceuticals – a biotech AZ purchased for $443m in 2013.

Latest news

  • Teva launches first generic of GSK's Lovaza in US Teva launches first generic of GSK's Lovaza in US

    GSK acquired US rights to Lovaza - which was originally developed by Norway's Pronova BioPharma - when it took over Reliant Pharmaceuticals in 2008 for $1.7bn. ... AZ acquired Epanova along with developer Omthera Pharmaceuticals in July 2013 in a $443m

  • Soriot says pipeline will speed recovery at AZ Soriot says pipeline will speed recovery at AZ

    Last year it bought respiratory company Pearl Therapeutics in a $1.15bn deal as well as biopharma companies AlphaCore Pharma, Spirogen, Amplimmune and Omthera Pharmaceuticals.

  • AZ said to be eyeing Forest takeover bid AZ said to be eyeing Forest takeover bid

    $500m. Earlier this year it bought respiratory company Pearl Therapeutics in a $1.15bn deal as well as US biotechs AlphaCore Pharma and Omthera Pharmaceuticals.

  • FDA to review AZ's fish oil drug Epanova FDA to review AZ's fish oil drug Epanova

    Hypertriglyceridaemia treatment acquired as part of Omthera takeover. AstraZeneca (AZ) is starting to see the fruits of its series of pipeline-boosting acquisitions in the past year with US regulators accepting ... Review is expected to be completed by

  • AZ adds to pipeline again with Amplimmune buy AZ adds to pipeline again with Amplimmune buy

    Therapeutics in a $1.15bn deal along with US biotechs AlphaCore Pharma and Omthera Pharmaceuticals earlier this year.

More from news
Approximately 1 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Pharma deals during November 2012 Pharma deals during November 2012

    closely followed by Omthera Pharmaceuticals' Epinova, not to mention the growing concerns regarding the health benefits of premium priced prescription omega-3 fatty acids. Perhaps this is reflected in an offer ... Discovery research alliance.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics